Latest News

Tuesday, October 21, 2014 | Glaucoma

Ivantis Announces HYDRUS II Glaucoma Study Met Primary Endpoint In a Randomized Controlled Trial at 2 Years

Ivantis, developer of the Hydrus Microstent, announced that the international HYDRUS II trial met its primary endpoint, according to a company news release. Results of the randomized, controlled study…

Read the full story

Tuesday, October 21, 2014 | Medical Studies

A Study Commissioned by the Israeli Air Force, Using GlassesOff App, Shows Air Force Pilots Gain Significant Improvement in Visual Acuity, Image Processing Speed

GlassesOff Inc. announced that statistically significant interim results from a study commissioned by the Israeli Air Force (IAF) demonstrated significant improvements in critical visual functions of …

Read the full story

Tuesday, October 21, 2014 | Earnings & Financials , Valeant Ophthalmics

Valeant Considering Raised Bid in Battle With Allergan

Valeant Pharmaceuticals International may raise its offer for Allergan, the company said after reporting better-than-expected third-quarter earnings and raising its 2014 forecast. Managers of Laval, Q…

Read the full story

Tuesday, October 21, 2014 | Acquisitions/Mergers

AbbVie Ends Purchase of Shire on U.S. Tax Rule Changes

AbbVie Inc. and Shire Plc agreed to terminate what would have been the biggest U.S. tax inversion after AbbVie pulled its support for the deal in the wake of proposed changes to U.S. rules governing s…

Read the full story

Monday, October 20, 2014 | Product Releases

Nextech Systems and MDIntelleSys Unveil Integrated, Cloud-Based EMR and Practice Management System

Nextech Systems announced the launch of its integrated ophthalmology cloud-based solutions at the AAO meeting in Chicago. Nextech and MDIntelleSys (MDI) unveiled a new, SaaS PM-EHR utilizing their com…

Read the full story

Monday, October 20, 2014 | Medical Studies

Ohr Pharmaceutical Announces Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study

Ohr Pharmaceutical announced positive clinical data from the IMPACT study at the AAO meeting in Chicago. The IMPACT study is a 9-month, phase 2 clinical trial evaluating Squalamine Eye Drops (OHR-102)…

Read the full story

Monday, October 20, 2014 | Product Releases

AAO Launches New Patient Education Materials to Meet Health Literacy Standards

Low literacy rates contribute to poor patient compliance, leading to increased hospitalizations and chronic illness and costing the economy between $106 -- $238 billion each year. To help address th…

Read the full story

Monday, October 20, 2014 | Clinical Trials

Allegro Ophthalmics Begins Phase 2 Clinical Trial of Luminate (ALG-1001) for the Treatment of Diabetic Macular Edema

Allegro Ophthalmics announced that it is enrolling patients in a phase 2 trial that will evaluate the safety and efficacy of Luminate, previously known as ALG-1001, in patients with diabetic macular e…

Read the full story

Monday, October 20, 2014 | Clinical Trials

R-Tech Ueno: Announcement of Initiation of the Phase I Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096

R-Tech Ueno has announced that the company has started a phase 1 clinical trial for the new molecular entity RTU-1096, which is a vascular adhesion protein-1 (VAP-1) inhibitor having anti-inflammatory…

Read the full story

Sunday, October 19, 2014 | Retina

DE-109 Effective in Treating Uveitis, Study Shows

Sunil K. Srivastava, MD, presented data on SAKRA, a stage 3, multinational, multicenter, randomized, double-masked clinical trail testing the safety and efficacy of intravitreal injections of DE-109 (…

Read the full story

Sunday, October 19, 2014 | Product Releases , Heidelberg Engineering

Heidelberg Engineering Announces Launch of OCT2 Spectralis OCT Module

Heidelberg Engineering GmbH announced the launch of strongOCT2/strong, the next-generation OCT module for Spectralis diagnostic imaging, according to a company news release. The strongOCT2 /strongmodu…

Read the full story

Sunday, October 19, 2014 | Health Care

American Academy of Ophthalmology Announces Key Milestones for its IRIS Ocular Disease Database

The American Academy of Ophthalmology announced key milestones in the development of an innovative quality of care initiative launched less than a year ago, according to an AAO news release. In presen…

Read the full story

Saturday, October 18, 2014 | Product Releases , Heidelberg Engineering

Heidelberg Engineering Launches New Image Management and Device Integration Platform

Heidelberg Engineering GmbH announced the launch of an ophthalmic picture archiving and communication system (PACS) platform at the AAO meeting in Chicago. HEYEX PACS evolves from the HEYEX (Heidelber…

Read the full story

Saturday, October 18, 2014 | Retina

Two Trials Showed Visual Gains at 52 Weeks with Conbercept

Peter Kaiser, MD, presented the results of several trials testing the safety and efficacy of conbercept, an anti-VEGF agent approved in China for the treatment of wet age-related macular degeneration …

Read the full story

Saturday, October 18, 2014 | Product Releases , Carl Zeiss Meditec

Zeiss Introduces New Products in its Essential Line to the US Market

Carl Zeiss Meditec announced new products in the Essential Line being introduced for US eye care providers. The products include the VISUPHOR 500 digital phoropter and the VISUSCREEN 100/500 acuity ch…

Read the full story
Load More

Advertisement

 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $21.75  0.00% 
 Akorn, Inc. $41.29  0.00% 
 Alimera Sciences, Inc. $4.77  0.00% 
 Allergan, Inc. $186.16  0.00% 
 Bayer $133.25  0.00% 
 Can-Fite Biopharma $3.12  0.00% 
 Carl Zeiss Meditec $20.77  0.00% 
 Cooper Companies, Inc. $156.55  0.00% 
 Escalon Medical Corp. $1.34  0.00% 
 Essilor International $105.00  0.00% 
 Imprimis Pharmaceuticals, Inc. $7.90  0.00% 
 InSite Vision, Inc. $0.29  0.00% 
 IRIDEX Corporation $7.29  0.00% 
 Johnson & Johnson $100.36  0.00% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $47.53  0.00% 
 Merck & Company, Inc. $55.13  0.00% 
 NicOx $2.06  0.00% 
 NovaBay Pharmaceuticals, Inc. $0.77  0.00% 
 Novartis AG Common Stock $88.61  0.00% 
 Ophthotech Corporation $39.88  0.00% 
 Quantel $3.38  0.00% 
 Roche $36.39  0.00% 
 STAAR Surgical Company $10.48  0.00% 
 TearLab Corporation $3.00  0.00% 
 TLC Vision Corp $0.00  0.00% 
 Topcon Corporation $22.13  0.00% 
 Valeant Pharmaceuticals $130.38  0.00%